Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Signal Transduction

A Macrophage-Dominant PI3K Isoform Controls Hypoxia-Induced HIF1α and HIF2α Stability and Tumor Growth, Angiogenesis, and Metastasis

Shweta Joshi, Alok R. Singh, Muamera Zulcic and Donald L. Durden
Shweta Joshi
1UCSD Department of Pediatrics, Moores Cancer Center, University of California, La Jolla, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alok R. Singh
1UCSD Department of Pediatrics, Moores Cancer Center, University of California, La Jolla, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Muamera Zulcic
1UCSD Department of Pediatrics, Moores Cancer Center, University of California, La Jolla, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald L. Durden
1UCSD Department of Pediatrics, Moores Cancer Center, University of California, La Jolla, California.
2Division of Pediatric Hematology-Oncology, UCSD Rady Children's Hospital, San Diego, California.
3SignalRx Pharmaceuticals, San Diego, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ddurden@ucsd.edu
DOI: 10.1158/1541-7786.MCR-13-0682 Published October 2014
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Deletion of PTEN in myeloid cells increase hypoxic HIF1α and HIF2α accumulation. A, Western blot analysis showing deletion of PTEN in myeloid cells. Cell lysates from BMDMs isolated from PTENMC-KO or PTENMC-Wt mice were subjected to Western blot analysis for PTEN, pAKT, and AKT. β-Actin was used as loading control. B and C, BMDMs isolated from PTENMC-WT and PTENMC-KO (B) and PTEN+/+ and PTEN+/− (C) mice were incubated under hypoxic (1% O2) conditions for 4 hours followed by preparation of nuclear extracts (for HIF1α and HIF2α) and Western blot analysis. Each lane in A, B, and C represents lysate prepared from individual mice. Mouse ID numbers are provided for each genotype. D, mRNA was isolated from PTENMC-WT and PTENMC-KO BMDMs incubated under hypoxia (1% O2) for 24 hours. VEGF mRNA expression was measured by real-time PCR. Data represent mean ± SEM (n = 3 or 4; P < 0.001; pairwise 2-sided Student t test). E, BMDMs isolated from PTENMC-KO mice were transfected with 5 μg of HA-PTEN, using AMAXA mouse macrophage Nucleofaction kit. After 36 hours of transfection, cells were exposed to normoxia (21% O2) or hypoxia (1% O2) for 4 hours followed by preparation of either nuclear extracts (for HIFα blots) or WCE (PTEN blot) and Western blot analysis. Experiments were repeated 4 to 5 times with 2 to 3 mice in each group.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    PI3K/AKT signaling axis control HIFα/VEGF axis. A and B, BMDMs from WT animals were treated with different concentrations of PI3K inhibitors (500 nmol/L PF4691502, PI-103, BKM120 and 25 μmol/L SF1126) followed by hypoxia for 4 hours for Western blots or 24 hours for real-time PCR studies. These macrophages were either used for lysate preparation (nuclear extracts for HIFα or WCE for pAKT and AKT) and Western blot analysis (A) or RNA and real-time PCR for VEGF (B). C and D, WT BMDMs were treated with different concentrations of SF2523 (10, 20, and 50 μmol/L) followed by hypoxia for 4 hours for Western blot analyses (C) or 24 hours for RNA isolation and real-time PCR for VEGF (D). E and F, BMDMs from WT animals were transfected with either 5 μg of myrAKT plasmid or 100 nmol/L control siRNA or 100 nmol/L siRNA against AKT1/2 using Amaxa Mouse Macrophage Nucleofaction kit (Lonza). Thirty-six hours after transfection, hypoxia was given to these transfected BMDMs for 4 hours followed by cell lysate preparation and Western blot analysis. Graphs in B and D represent mean ± SEM (n = 3–4). Statistical significance is assessed by 2-sample t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Experiments were repeated 3 to 4 times with similar results.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Specific p110γ and p110δ isoform of PI3K control HIFα/VEGF axis in macrophages. A and B, BMDM from WT animals were treated with 100 nmol/L of GDC0941or TGX221or Cal101 or AS605240 followed by hypoxia for 4 hours for Western blot analysis or 24 hours for RNA isolation and real-time PCR analysis. C and D, BMDMs from WT animals were transfected with either 100 nmol/L control siRNA or siRNA against p110 α or β or δ or γ isoform using Amaxa Mouse Macrophage Nucleofaction kit (Lonza). Thirty-six hours after transfection, hypoxia was given to these siRNA-transfected BMDMs for 4 hours for Western blot analysis (C) or 24 hours for RNA isolation and real-time PCR analysis (D). E, Western blot analysis of HIF1α and HIF2α from WT and p110γ−/− BMDMs kept in hypoxic (1% O2) conditions for 4 hours followed by preparation of nuclear extracts. Each lane in figure represents lysate prepared from an individual mouse. F, relative VEGF expression in WT, p110 γ−/− BMDMs treated with or without 100 nmol/L AS605240 and kept in hypoxia (1% O2) for 24 hours, followed by RNA isolation and real-time PCR studies. Graphs in B, D, and F represent mean ± SEM (n = 4–5) for 3 independent experiments. Statistical significance is assessed by 2-sample t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Hypoxic degradation of HIF1α and HIF2α by PTEN/PI3K/AKT pathway occurs via the 26S proteasome. A, Western blot analysis of HIF1α and HIF2α from BMDMs from PTENMC-WT and PTENMC-KO treated with 10 μmol/L MG132 and kept in hypoxic conditions for 4 hours. B–D, WT BMDMs were treated with 10 μmol/L proteasome inhibitor MG132 for 5 minutes before being pulsed with the pan-PI3K inhibitors, 25 μmol/L SF1126, and 500 nmol/L PF4691502 (B), 100 nmol/L AS605240 (C), and 10 μmol/L SF2523 (D) followed by normoxia (21% O2) or hypoxia (1% O2) for 4 hours. Nuclear extracts were prepared for HIFα. Western blot analyses are as described before. Experiments were repeated 3 to 4 times with similar results.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Expression of p110γ isoform in macrophages promotes tumor growth and angiogenesis. A, tumor growth of LLC cells inoculated subcutaneously in WT and p110γ−/− mice (n = 6–8). B, left, representative immunofluorescent staining of tumor vasculature by CD31 (green) and counterstain by DAPI (blue) on frozen tumor sections of LLC tumors implanted subcutaneously in WT and p110γ−/− mice. Right, reduced microvascular density (MVD) in tumors isolated from p110γ−/− animals as compared with WT animals. MVD was determined by counting the number of microvessels per high-power field (HPF) in the section with an antibody reactive to CD31. Microvessels were counted blindly in 5 to 10 randomly chosen fields, and data are representative of 3 independent experiments with 4 to 5 mice. *, P < 0.05 versus WT. C, relative expression levels of specific genes required for tumor growth in macrophages sorted from LLC tumors implanted into WT and p110γ−/− animals. D, left, representative photograph of pulmonary metastatic foci produced 15 days after intravenous injection of B16F10 cells in WT and p110γ−/− mice. Right, number of experimental pulmonary B16F10 metastases in lungs counted under dissecting microscope. E, expression of specific tumor-promoting genes in the BMDMs isolated from WT and p110γ−/− mice and cultured in MCSF in vitro. Graphs present mean ± SEM of 7 mice for A, B, and D and 3 to 4 mice for C. *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus WT, as determined using 2-sample t test.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    SF1126, a pan-PI3K inhibitor blocks tumor growth, angiogenesis, metastasis and reduces the expression of proangiogenic factors by TAMs. A, tumor volume of LLC inoculated subcutaneously in WT mice treated with or without 50 mg/kg SF1126 3 times a week. Treatment was started 10 days after inoculation of LLC cells and was continued until tumors were harvested (n = 6–8). B, MVD was scored by manual counting of CD31-positive vessels in subcutaneous LLC tumor sections was reduced in tumors isolated from WT animals treated with SF1126. Right, reduced microvascular density in tumors isolated from untreated or SF1126-treated animals as confirmed by quantification of CD31-positive area in high-power field (HPF) C, relative expression levels of specific genes required for tumor growth in macrophages sorted from LLC tumors implanted into WT mice and treated with 50 mg/kg of SF1126, 3 times a week until tumors were harvested. D, left, representative photograph of pulmonary metastatic foci produced in WT animals injected with B16F10 melanoma and treated with daily dose of 50 mg/kg SF1126 for 15 days. Right, number of experimental pulmonary B16F10 metastases in lungs. E, figure shows representative lung hematoxylin and eosin (H&E) sections of B16 metastases from WT mice treated with or without 50 mg/kg SF1126. Arrows point to metastatic foci. F, Kaplan–Meier survival curve for B16 metastasized mice treated with or without 50 mg/kg SF1126 daily. Data are representative of 2 to 3 independent experiments. Graphs present mean ± SEM of 8 to 10 mice for A, B, and D–F and 3 to 4 mice for C. *, P < 0.05 and **, P < 0.01 versus WT, as determined using 2-sample t test.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Mechanism by which the PTEN/PI3K/AKT signaling axis exerts control over HIFα stability, tumor growth, and metastasis by secretion of proangiogenic factors by macrophages. PI3K inhibitors block the phosphorylation of an E3 ligase resulting in cytoplasmic localization of E3 ligase and degradation of HIF1α; this could have therapeutic implications for HIF1α/VEGF axis in PI3K inhibitor cancer therapeutics.

Additional Files

  • Figures
  • Supplementary Figure Legend

    Files in this Data Supplement:

    • Supplementary Figure Legend
    • Supplementary Figure S1 - Relative mRNA and protein expression level of PI-3 kinase isoforms in macrophages.
PreviousNext
Back to top
Molecular Cancer Research: 12 (10)
October 2014
Volume 12, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Macrophage-Dominant PI3K Isoform Controls Hypoxia-Induced HIF1α and HIF2α Stability and Tumor Growth, Angiogenesis, and Metastasis
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Macrophage-Dominant PI3K Isoform Controls Hypoxia-Induced HIF1α and HIF2α Stability and Tumor Growth, Angiogenesis, and Metastasis
Shweta Joshi, Alok R. Singh, Muamera Zulcic and Donald L. Durden
Mol Cancer Res October 1 2014 (12) (10) 1520-1531; DOI: 10.1158/1541-7786.MCR-13-0682

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Macrophage-Dominant PI3K Isoform Controls Hypoxia-Induced HIF1α and HIF2α Stability and Tumor Growth, Angiogenesis, and Metastasis
Shweta Joshi, Alok R. Singh, Muamera Zulcic and Donald L. Durden
Mol Cancer Res October 1 2014 (12) (10) 1520-1531; DOI: 10.1158/1541-7786.MCR-13-0682
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Epigenetic Silencing of Thy1 in CD44+/CD24low/CD90+ Myoepithelial Cells
  • ERK Inhibitor Response in KRAS-Mutant Cancer Models
  • Nuclear E-Cadherin Acetylation Enhance β-Catenin Activity
Show more Signal Transduction
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement